Go Deep
Emergent BioSolutions Inc.
Emergent BioSolutions Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,467 | -2.0 | 1.04 | 1.72 | 658.06 |
| Oct 2026 | 19,467 | -2.0 | 1.04 | 1.72 | 656.09 |
| Oct 2026 | 19,351 | -2.1 | 1.08 | 1.72 | 681.82 |
| Oct 2026 | 19,696 | -1.9 | 0.96 | 1.72 | 604.28 |
| Oct 2026 | 19,704 | -1.9 | 0.95 | 1.72 | 603.03 |
| Oct 2026 | 19,734 | -1.9 | 0.94 | 1.72 | 596.40 |
| Oct 2026 | 19,773 | -1.8 | 0.93 | 1.72 | 586.41 |
| Oct 2026 | 19,760 | -1.8 | 0.94 | 1.72 | 588.05 |
| Oct 2026 | 19,760 | -1.8 | 0.94 | 1.72 | 590.49 |
Emergent BioSolutions Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 226,800,000.0 | 149,700,000.0 | 143,800,000.0 | 222,000,000.0 |
| Net Profit | -180,200,000.0 | 6,800,000.0 | -54,600,000.0 | 51,200,000.0 |
| EPS | -3.5 | 0.1 | -1.0 | 1.0 |
Emergent BioSolutions Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 705,200,000.0 | 1,013,600,000.0 | 1,023,000,000.0 | 1,076,100,000.0 |
| Net Profit | 52,600,000.0 | -190,600,000.0 | -760,500,000.0 | -211,600,000.0 |
| EPS | 1.0 | -3.6 | -14.8 | -4.5 |
Emergent BioSolutions Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 1,318,600,000.0 | 1,389,700,000.0 | 1,823,200,000.0 | 3,166,300,000.0 | — |
| Total Liabilities | 796,000,000.0 | 906,900,000.0 | 1,173,900,000.0 | 1,778,600,000.0 | — |
| Total Equity | 522,600,000.0 | 482,800,000.0 | 649,300,000.0 | 1,387,700,000.0 | — |
Owes vs Owns
Emergent BioSolutions Inc. owed $0.69 for every $1 it owned in Jun 2026, up from $0.56 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.69× | 0.60× | 0.65× | 0.64× | 0.56× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Emergent BioSolutions Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 15.6%Receivables 6.4%Inventory 26.0%Fixed assets (tangible) 15.6%Intangible assets 33.1%Other assets 3.3%
How it's funded — Dec 2025
Long-term debt 43.4%Payables 4.2%Other liabilities 12.8%Shareholders' equity 39.6%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 205.4 | 99.5 | 111.7 | 642.6 |
| Receivables | 84.2 | 154.5 | 191.0 | 159.2 |
| Inventory | 343.4 | 311.7 | 328.9 | 350.7 |
| Fixed assets (tangible) | 205.4 | 270.6 | 382.8 | 817.6 |
| Intangible assets | 436.5 | 501.5 | 566.6 | 947.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 43.7 | 51.9 | 242.2 | 249.2 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 413.7 | 957.3 |
| Long-term debt | 572.1 | 663.7 | 446.5 | 448.5 |
| Payables | 55.6 | 60.9 | 112.2 | 103.5 |
| Other liabilities | 168.3 | 182.3 | 201.5 | 269.3 |
| Shareholders' equity | 522.6 | 482.8 | 649.3 | 1,387.7 |
| Net tangible assets | 86.1 | -18.7 | 82.7 | 440.7 |
Emergent BioSolutions Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 170,600,000.0 | 58,700,000.0 | -206,300,000.0 | -34,100,000.0 | — |
| Investing Activities | 69,400,000.0 | 125,200,000.0 | 212,300,000.0 | -381,300,000.0 | — |
| Financing Activities | -136,600,000.0 | -190,000,000.0 | -535,700,000.0 | 481,200,000.0 | — |